In Soo Kim

7202246, Apr 10, 2007

Jun 8, 2005

11/147520

Zhenkun Ma - Dallas TX, US
In Ho Kim - Lewisville TX, US
Jing Li - Dallas TX, US

Cumbre Pharmaceuticals Inc. - Dallas TX

C07D 225/04
A61K 31/495
A61P 31/04

514250, 540453, 540457

Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.

7226931, Jun 5, 2007

Jul 21, 2005

11/186425

Charles Z. Ding - Plano TX, US
Zhenkun Ma - Dallas TX, US
Jing Li - Dallas TX, US
Susan Harran - Dallas TX, US
Yong He - Arlington TX, US
Keith P. Minor - Dallas TX, US
In Ho Kim - Lewisville TX, US
Jamie C. Longgood - Carrollton TX, US
Yafei Jin - Dallas TX, US
Keith D. Combrink - Fort Worth TX, US

Cumbre Pharmaceuticals Inc. - Dallas TX

C07D 498/08
A61K 31/4709
A61P 31/04

514306, 540458, 548138, 548208

Rifamycin derivatives having the following structure of general formula I (both hydroquinone and corresponding quinone (C-C) forms):.

7229996, Jun 12, 2007

Jul 21, 2005

11/186187

Zhenkun Ma - Dallas TX, US
Jing Li - Dallas TX, US
Susan Harran - Dallas TX, US
Yong He - Arlington TX, US
Keith P. Minor - Dallas TX, US
In Ho Kim - Lewisville TX, US
Charles Z. Ding - Plano TX, US
Jamie C. Longgood - Carrolton TX, US
Yafei Jin - Dallas TX, US
Keith D. Combrink - Fort Worth TX, US

Cumbre Pharmaceuticals Inc. - Dallas TX

C07D 498/08
A61K 31/4709
A61P 31/04

51425217, 514278, 514306, 540459

Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C-C) forms):.

7238694, Jul 3, 2007

Jan 12, 2005

11/034279

Charles Z. Ding - Plano TX, US
Yafei Jin - Dallas TX, US
Jamie C. Longgood - Carrollton TX, US
Zhenkun Ma - Dallas TX, US
Jing Li - Dallas TX, US
In Ho Kim - Flower Mound TX, US
Keith P. Minor - Dallas TX, US
Susan Harran - Dallas TX, US

Cumbre Pharmaceuticals, Inc. - Dallas TX

C07D 498/08
C07D 519/00
A61K 31/4709
A61K 31/496
A61P 31/04

51425304, 51425308, 514312, 540456

The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

7247634, Jul 24, 2007

Jan 12, 2005

11/034195

Zhenkun Ma - Dallas TX, US
Yafei Jin - Dallas TX, US
Jing Li - Dallas TX, US
Charles Z. Ding - Plano TX, US
Keith P. Minor - Dallas TX, US
Jamie C. Longgood - Carrollton TX, US
In Ho Kim - Flower Mound TX, US
Susan Harran - Dallas TX, US
Keith Combrink - Fort Worth TX, US
Timothy W. Morris - Coppell TX, US

Cumbre Pharmaceuticals Inc. - Dallas TX

C07D 498/08
A61K 31/395
A61P 31/04

51425304, 51425308, 514278, 514300, 514312, 540456

Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.

7678791, Mar 16, 2010

Jul 12, 2007

11/827467

Charles Z. Ding - Plano TX, US
In Ho Kim - Dublin OH, US
Jiancheng Wang - Addison TX, US
Zhenkun Ma - Westfield NJ, US
Yafei Jin - Ann Arbor MI, US
Keith D. Combrink - Arlington TX, US
Genliang Lu - Plano TX, US
A. Simon Lynch - Dallas TX, US

Cumbre IP Ventures, L.P. - Dallas TX

C07D 498/22
A61K 31/535
A61P 31/00

5142305, 5142328, 51425211, 51425402, 51425406, 51425407, 540453, 540456, 540457, 540458

Substituted rifamycin derivatives in which a nitroimidazole, nitrothiazole or nitrofuran pharmacophore is covalently bonded to a rifamycin, methods of using the rifamycin derivatives, and pharmaceutical compositions containing the rifamycin derivatives are disclosed. Methods of synthesizing these substituted rifamycin derivatives are also disclosed. The rifamycin derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.

20050118624, Jun 2, 2005

Sep 30, 2004

10/954996

Zhenkun Ma - Dallas TX, US
Jing Li - Dallas TX, US
In Kim - Irving TX, US
Yafei Jin - Dallas TX, US
Anthony Lynch - Dallas TX, US
Eric Roche - Carrollton TX, US
Doug Beeman - Dallas TX, US

Cumbre Inc. - Dallas TX

C12Q001/68
C07H017/08
C07H021/04

435006000, 536024100, 536025320, 544229000, 544230000, 536007100

Fluorescent probes that have binding affinity to ribosomes. The fluorescent probes are useful tools for identifying small molecules that bind to the 50S or 30S subunits of the bacterial and other ribosomes and serve as novel ribosome inhibitors. These probes are also useful for determining the interactions between a specific ligand and the ribosome.

43830455, May 10, 1983

Apr 27, 1982

6/372413

Dennis C. Nagle - Catonsville MD
Myron T. McCall - Charlotte NC
In H. Kim - Sykesville MD

Martin Marietta Corp. - Bethesda MD

C04B 3504

501109

Gunning mixes and other magnesia-based refractory compositions are disclosed which include up about to 10% by weight sulfamic acid as a binder. Sulfamic acid reacts readily with periclase grain and, when employed with boric acid and ceramic sintering aids forms an excellent binder system.